Assessing patient-reported peripheral neuropathy

The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

Ellen M Lavoie Smith, Debra L. Barton, Rui Qin, Preston D. Steen, Neil K. Aaronson, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.

Original languageEnglish (US)
Pages (from-to)2787-2799
Number of pages13
JournalQuality of Life Research
Volume22
Issue number10
DOIs
StatePublished - Dec 2013

Fingerprint

Peripheral Nervous System Diseases
Reproducibility of Results
Drug Therapy
Research
Neoplasms
Pain
Statistical Factor Analysis
Therapeutics
Hearing Loss
Surveys and Questionnaires
Lower Extremity
Equipment and Supplies

Keywords

  • Chemotherapy
  • EORTC QLQ-CIPN20
  • Peripheral neuropathy
  • Reliability
  • Validity

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

Assessing patient-reported peripheral neuropathy : The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. / Smith, Ellen M Lavoie; Barton, Debra L.; Qin, Rui; Steen, Preston D.; Aaronson, Neil K.; Loprinzi, Charles Lawrence.

In: Quality of Life Research, Vol. 22, No. 10, 12.2013, p. 2787-2799.

Research output: Contribution to journalArticle

@article{763d399450a4441a85ae8822844cdfbf,
title = "Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire",
abstract = "Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.",
keywords = "Chemotherapy, EORTC QLQ-CIPN20, Peripheral neuropathy, Reliability, Validity",
author = "Smith, {Ellen M Lavoie} and Barton, {Debra L.} and Rui Qin and Steen, {Preston D.} and Aaronson, {Neil K.} and Loprinzi, {Charles Lawrence}",
year = "2013",
month = "12",
doi = "10.1007/s11136-013-0379-8",
language = "English (US)",
volume = "22",
pages = "2787--2799",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Assessing patient-reported peripheral neuropathy

T2 - The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

AU - Smith, Ellen M Lavoie

AU - Barton, Debra L.

AU - Qin, Rui

AU - Steen, Preston D.

AU - Aaronson, Neil K.

AU - Loprinzi, Charles Lawrence

PY - 2013/12

Y1 - 2013/12

N2 - Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.

AB - Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.

KW - Chemotherapy

KW - EORTC QLQ-CIPN20

KW - Peripheral neuropathy

KW - Reliability

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=84892782989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892782989&partnerID=8YFLogxK

U2 - 10.1007/s11136-013-0379-8

DO - 10.1007/s11136-013-0379-8

M3 - Article

VL - 22

SP - 2787

EP - 2799

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 10

ER -